Showing 2421-2430 of 3039 results for "".
- Eylea Approved as First Pharmacologic Treatment of Preterm Infants with ROPhttps://modernod.com/news/eylea-approved-as-first-pharmacologic-for-treatment-of-preterm-infants-with-rop/2481400/The FDA has approved Eylea (aflibercept) to treat preterm infants with retinopathy of prematurity (ROP). Following this first pediatric approval, Eylea is now indicated to treat five retinal conditions caused by ocular angiogenesis. “Retinopathy of prematurity is a leadi
- Orbis Announces 3-Year Partnership with Hoya Vision Carehttps://modernod.com/news/orbis-announces-3-year-partnership-with-hoya-vision-care/2481389/Eye care nonprofit Orbis International announced a renewed partnership with Hoya, which will commit its support over the next 3 years with a focus on helping school children get access to eye care in low- to middle-income countries, and on training eye care professionals around the world thr
- Endogena Therapeutics Receives FDA Fast Track Designation for EA-2353 for the Treatment of Retinitis Pigmentosahttps://modernod.com/news/endogena-therapeutics-receives-fda-fast-track-designation-for-ea-2353-for-the-treatment-of-retinitis-pigmentosa/2481387/The FDA has granted Fast Track designation to Endogena Therapeutics' EA-2353 for the treatment of retinitis pigmentosa (RP). EA-2353 takes a novel, small-molecule approach and selectively activates endogenous retinal stem and progenitor cells, which differentiate into
- Alcon Canada Launches TOTAL Toric Lenses for Astigmatic Patientshttps://modernod.com/news/alcon-canada-launches-total-toric-lenses-for-astigmatic-patients/2481383/Alcon announced the Canadian launch of Total30 for Astigmatism and Dalies Total1 for Astigmatism, extending Alcon’s portfolio of reusable and daily disposable lenses for astigmatic patients. Estimates show that toric lenses is the fastest growing
- Research Challenges “Sugar Hypothesis” of Diabetic Cataract Developmenthttps://modernod.com/news/research-challenges-sugar-hypothesis-of-diabetic-cataract-development/2481371/New findings from investigators at Brigham and Women’s Hospital, a founding member of the Mass General Brigham health care system, contradict previous notions about sugar’s role i
- Dr. Reddy's Launches Generic Version of Durezol in the UShttps://modernod.com/news/dr-reddys-launches-generic-version-of-durezol-in-the-us/2481368/Following FDA approval, Dr. Reddy’s Laboratories announced the US launch of "Dr. Reddy’s Difluprednate Ophthalmic Emulsion 0.05%," a therapeutic generic equivalent to Durezol (Difluprednate Ophthalmic Emulsion 0.05%; Novartis), according to a company news release.
- Harrow Completes Acquisition of US Rights to Five Branded Ophthalmic Drugshttps://modernod.com/news/harrow-closes-acquisition-of-us-rights-to-ilevro-nevanac-vigamox-maxidex-and-triesence-and-will-begin-receiving-net-profit-payments-for-acquired-products/2481361/Harrow announced the closing of its previously announced acquisition with Novartis of the exclusive US commercial rights to five branded ophthalmic products: Ilevro, Nevanac, Vigamox, Maxidex, and Triesence. In December, Harrow announced it had 
- Bausch + Lomb Acquires AcuFocushttps://modernod.com/news/bausch-lomb-acquires-acufocus/2481353/Bausch + Lomb announced it has acquired AcuFocus, maker of the IC-8 Apthera IOL. Financial terms of the deal were not disclosed. The moves bolsters Bausch + Lomb's cataract surgery portfolio. AcuFocus' IC-8 was approved by the FDA in July
- Keranova Announces Clinical Study Results for Robotic Laser Technologyhttps://modernod.com/news/keranova-announces-clinical-study-results-for-robotic-laser-technology/2481345/Keranova announced the finalization of the regulatory clinical studies of FemtoMatrix, its robotic laser technology. With the positive results, the company said it will now apply for CE marking for this new class of surgical equipment in cataract surgery. According to Ker
- AcuFocus Announces First Commercial Patients Treated With the IC-8 Apthera IOLhttps://modernod.com/news/acufocus-announces-first-commercial-patients-treated-with-the-ic-8-apthera-iol/2481329/AcuFocus announced that Vance Thompson, MD, of Vance Thompson Vision, Sioux Falls, South Dakota has commercially implanted the first patients with the IC-8 Apthera IOL. The first and only small aperture, non-toric extended depth of focus IOL, the Apthera IOL is FDA approved fo